Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 12, 2013) - biOasis Technologies Inc. (TSX VENTURE:BTI)(OTCBB:BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, reported that new research conducted under its BT2111 (Herceptin®) program shows that BT2111-a conjugate of the metastatic cancer drug, Herceptin-not only crosses the blood-brain barrier, but also penetrates the blood-tumor barrier up to 10 times better than Herceptin alone.

BT2111 was developed by biOasis's drug delivery platform, Transcend, which offers the creation of a new class of drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of metastatic cancer, as well as other brain diseases, like neurodegeneration and metabolic disease.

"Through image analysis and quantitative autoradiography in this animal study, we've now demonstrated that BT2111 distributed evenly in healthy sections of the brain, surrounded the metastatic brain cancer, and was present at significantly greater levels within the tumors compared to equal to or lower dose equivalence of Herceptin alone," said Rob Hutchison, CEO of biOasis Technologies. "This observation corroborates the therapeutic responses seen in our prior animal models."

"Treating cancer is extremely challenging as it is, but with brain tumors we have the additional hurdles of the blood-brain and blood-tumor barriers," continued Hutchison. "Unfortunately, metastatic forms of brain cancer are even more problematic. MedlinePlus has reported that for many people with metastatic brain tumors the cancer is not curable. It will eventually spread to other areas of the body, with death often occurring within two years. This grim statistic has been a major compelling factor for us initiating the BT2111 program."

"Understanding the mechanisms of actions of BT2111 is pivotal in the development of new therapeutic options for the treatment of HER2-positive metastatic brain cancer and other forms of metastatic brain cancers," added Hutchison. "We are continuing our BT2111 program at a number of locations."

In the treatment of brain tumors, drug delivery is complicated by the presence of the blood- brain barrier (BBB). The variability of the BBB and heterogeneity in permeability of the blood- tumour barrier (BTB) depends on tumor type, size, location, and prior treatments. There is complexity in the tumor microvessel populations (the brain-tumour barrier) that feed the growing metastatic cancer cells in the brain. The BTB remains a significant impediment to the use of standard chemotherapeutic delivery and efficacy in brain metastases of breast cancer. Recent research with anti-angiogenic treatment demonstrated that glioblastomas can continue to grow and even increase tissue invasion without the need for a second wave of angiogenesis. These findings indicate that primary brain tumors proliferate behind an intact BBB and that this barricade has to be crossed by any drug aimed to affect tumor growth.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more information about the company please visit www.bioasis.ca.

Herceptin® is a registered trademark of Genentech/Roche.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward- looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Rob Hutchison Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"